This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $185,579 to the University of Texas Southwestern Medical Center to conduct research aimed at identifying pre-transplant biomarkers associated with acute rejection in heart transplant recipients. The research will use proteomic profiling, RNA sequencing, and machine learning approaches to develop an integrated signature to predict rejection risk. A sub-award of unstated amount was provided to Duke University to perform sample processing, proteomic analysis, and statistical support for the project. The goal is to enable safer minimization of immunosuppression in low-risk heart transplant recipients and improve outcomes. The award period runs from September 1, 2024 to June 30, 2029.
Generated 3/4/25, 8:44 AM